Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: Results of a phase II trial

Haematologica

Volumn 101, Issue 5, 2016, Pages e192-e195

  Spaner, David E ^a,b,c,d   Wang, Guizhei ^a   McCaw, Lindsay ^a   Li, Yanmei ^a   Disperati, Patricia ^e   Cussen, Mary Ann ^c   Shi, Yonghong ^a  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO EAST GENERAL HOSPITAL   (Canada)

Author keywords

Chronic lymphocytic leukemia; Ibrutinib; Janus kinases; Kinase inhibitors; Phosphoproteome; Ruxolitinib; STAT3

Indexed keywords

BETA 2 MICROGLOBULIN; FLUDARABINE; IBRUTINIB; MICRORNA; MICRORNA 17; RITUXIMAB; RUXOLITINIB; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; JANUS KINASE; PYRAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; BLASTOMYCOSIS; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DEATH; DISEASE DURATION; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LETTER; LYMPHADENOPATHY; LYMPHOCYTOSIS; MALE; MAXIMUM PERMISSIBLE DOSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; SPLENECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; JANUS KINASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PYRAZOLES;

EID: 84964715394     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.135418     Document Type: Letter

References (15)

1. Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. 2015;126(4):471-477.
2. Tomic J, Lichty B, Spaner DE. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood. 2011;117(9):2668-2680.
3. Li Y, Shi Y, McCaw L, et al. Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. Blood. 2015;126(6):766-778.
4. Steele AJ, Prentice AG, Cwynarski K, et al. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood. 2010;116(22):4569-4577.
5. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
6. Del G, I, Mauro FR, Foa R. Chronic lymphocytic leukemia in less fit patients: "slow-go". Leuk Lymphoma. 2011;52(12):2207-2216.
7. Hallek M, Cheson BD, Catovsky D, et al. International workshop on chronic lymphocytic leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
8. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961;13:346-353.
9. Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119(20):4614-4618.
10. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment- naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.
11. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.
12. Spaner DE. Oral high-dose glucocorticoids and Ofatumumab in fludarabine- resistant Chronic Lymphocytic Leukemia. Leukemia. 2012; 26(5):1144-1145.
13. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843-3844.
14. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA. 2007;104(43):17069-17074.
15. Jain P, Keating M, Cleeland C, et al. Ruxolitinib reduces cytokine/chemokine levels and improves fatigue and chronic lymphocytic leukemia (CLL)-related symptoms in CLL patients not requiring systemic therapy. Blood (ASH annual meeting abstracts). 2015;126(21):abstract#3310.